

Chapter 149

Mastocytosis

Michael D. Tharp

REFERENCES

1. Caplan RM: The natural course of urticaria pigmentosa. *Arch Dermatol* **87**:146, 1963
2. Heide R, Tank B, Oranje AP: Mastocytosis in childhood. *Ped Dermatol* **19**:375, 2002
3. Valent P et al: "Mastocytosis (Mast cell disease)" In: *World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues*, edited by ES Jaffe et al. Lyon, IARC Press, 1:291-302, 2001.
4. Noto G, Pravata G, Arico M: Concordant urticaria pigmentosa in a couple of identical twins. A five-year follow up. *Acta Dermatol Venereol* **75**:499, 1995
5. Gay MW, Noojin RO, Finely WH: Urticaria pigmentosa discordant in identical twins. *Arch Dermatol* **102**:29, 1970
6. Cainelli T et al: Monozygotic twins discordant for cutaneous mastocytosis. *Arch Dermatol* **119**:1021, 1983
7. Rottem M et al: Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/FcεRI-cell population. *Blood* **84**:2489, 1994
8. Anderson DM et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. *Cell* **63**:235, 1990
9. Longley BJ et al: Chymase cleavage of stem cell factor yields a bioactive, soluble product. *Proc Natl Acad Sci USA* **94**:9017, 1998
10. Kulka M, Metcalfe DD: High-resolution tracking of cell division demonstrates differential effects of TH1 and TH2 cytokines on SCF-dependent human mast cell production in vitro: Correlation with apoptosis and Kit expression. *Blood* **105**:592, 2005
11. Lappalainen J, Lindstedt KA, Kovanen PT: A protocol for generating high numbers of mature and functional human mast cells from peripheral blood. *Clin Exper Allergy* **37**:1404, 2007
12. Longley BJ et al: Activating and dominant inactivating *c-kit* catalytic domain mutations in distinct clinical forms of human mastocytosis. *Proc Natl Acad Sci U S A* **96**:1609, 1999
13. Nagata H. et al: c-Kit mutation in a population of patients with mastocytosis. *Int Arch Allergy Immunol* **113**:184, 1997
14. Bodemer C et al: Pediatric mastocytosis is a clonal disease associated with D^{816V} *c-KIT* mutations. *J Invest Dermatol* **130**:804, 2010
15. Zappulla JP et al: Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. *J Exp Med* **202**:1635, 2005
16. Kettelhut BV, Metcalfe DD: Pediatric mastocytosis. *J Invest Dermatol* **96**:155, 1991
17. Worobec AS et al: Mastocytosis complicating pregnancy. *Obstet Gynecol* **95**:391, 2000
18. Brockow K et al: Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: Correlation with clinical patterns of disease. *Arch Dermatol* **138**:785, 2002
19. Valent P et al: Mastocytosis: Pathology, genetics and current options for therapy. *Leukemia Lymphoma* **46**:35, 2005
20. Sagher F, Even-Paz Z: *Mastocytosis and the Mast Cell*. Chicago, Yearbook Medical, 1967, pp. 10-291
21. Kasper C, Freeman RG, Tharp MD: Diagnosis of mastocytosis subsets using a morphometric point counting technique. *Arch Dermatol* **123**:1017, 1987
22. Kasprovicz S, Chan IJ, Tharp MD: Nodular Mastocytosis. *Arch Dermatol* **55**:347, 2006
23. Konrad FM, Schroeder TH: Anaesthesia in patients with mastocytosis. *Acta Anaesthesiol Scand* **53**:207, 2009
24. Jensen RT: Gastrointestinal abnormalities and involvement in systemic mastocytosis. *Hematol Oncol Clin North Am* **14**:579, 2000
25. Mican JM et al: Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases. *Hepatology* **22**:1163, 1995
26. Escribano L et al: Mastocytosis: Current concepts in diagnosis and treatment. *Ann Hematol* **81**:677, 2002
27. Lanternier F et al: Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. *PLoS One* **3**:1, 2008

28. Escribano L et al: Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish network on mastocytosis in a series of 145 patients. *J Allergy Clin Immunol* **124**:514, 2009
29. Travis WD, Li C-Y: Pathology of the lymph node and spleen in systemic mast cell disease. *Mod Pathol* **1**:4, 1986
30. Travis W et al: Systemic mast cell disease. *Medicine* **67**:345, 1988
31. Rogers MP et al: Mixed organic brain syndrome as a manifestation of systemic mastocytosis. *Psychosom Med* **48**:437, 1986
32. McFarlin KE, Kruesi MJ, Metcalfe DD: A preliminary assessment of behavioral problems in children with mastocytosis. *Int J Psychiatry Med* **21**:281, 1991
33. Lee HW et al: Two cases of telangiectasia macularis eruptive perstans demonstrated by immunohistochemistry for c-kit (CD117). *J Dermatol* **32**:817, 2005
34. Schwartz LB et al: The α form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. *J Clin Invest.* **96**:2702, 1995
35. Keyzer JL et al: Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. *N Engl J Med* **309**:1603, 1983
36. Brockow K et al: Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase. *J Allergy Clin Immunol* **109**:82, 2002
37. Akin C et al: Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. *Exp Hematol* **28**:140, 2000
38. Schwartz LB et al: The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. *J Clin Invest* **96**:2702, 1995
39. Kettelhut BV et al: A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis [see comments]. *J Allergy Clin Immunol* **83**:866, 1989
40. Horan RF, Sheffer AL, Austen KF: Cromolyn sodium in the management of systemic mastocytosis. *J Allergy Clin Immunol* **85**:852, 1990
41. Barton J et al: Treatment of urticaria pigmentosa with corticosteroids. *Arch Dermatol* **121**:1516, 1985
42. Kurosawa M et al: Response to cyclosporin and low dose methylprednisone in aggressive systemic mastocytosis. *J Allergy Clin Immunol* **103**:S412-S420, 1999
43. Czarnetzki BM et al: Phototherapy of urticaria pigmentosa: Clinical response and changes of cutaneous reactivity, histamine and chemotactic leukotrienes. *Arch Dermatol Res* **277**:105, 1985
44. Vella Briffa D et al: Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. *Br J Dermatol* **109**:67, 1983
45. Butterfield JH: Response of severe systemic mastocytosis to interferon alpha. *Br J Dermatol* **138**:489, 1998
46. Teferi A et al: Treatment of systemic mast cell disease with cladribine. *N Engl J Med* **344**:307, 2001
47. Pardanani A et al: Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. *Leuk Res* **28**:127-131, 2004
48. Akin C et al: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. *Blood* **103**:3222, 2004
49. Cools J et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. *N Engl J Med* **348**:1201, 2003
50. Vega-Ruiz A et al: Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. *Leuk Res* **33**:1481, 2009
51. Purtill D et al: Dasatinib therapy for systemic mastocytosis: Four cases. *Eur J Haematol* **80**:456, 2008
52. Friedman B et al: Splenectomy in the management of systemic mast cell disease. *Surgery* **107**:94, 1990
53. Johnstone PA et al: Radiotherapy of refractory bone pain due to systemic mast cell disease. *Am J Clin Oncol* **17**:328, 1994
54. Nakamura R et al: A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. *Bone Marrow Transplant* **37**:353, 2006